Galectin Therapeutics Inc.
GALT
$1.38
$0.010.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -19.71% | -7.59% | -35.74% | 0.33% | 5.99% |
| Total Depreciation and Amortization | 11.11% | 12.50% | 156.25% | -71.88% | 12.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -429.55% | 23.03% | 350.77% | 6.67% | -34.57% |
| Change in Net Operating Assets | -93.39% | -26.53% | 450.78% | -164.03% | 73.18% |
| Cash from Operations | -172.03% | -11.80% | 15.25% | -12.16% | 35.05% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | -- | 0.00% | 0.00% | 0.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -91.49% | -0.33% | 3.76% | 0.00% | 0.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -325.37% | -38.98% | 1,123.35% | -165.45% | 91.89% |